Interest Rate Environment / Biotech Funding: High inflation and the Fed's stance (FOMC Minutes, US CPI Data) impact interest rates. Biotechnology companies, often in development stages, heavily rely on external funding. Higher interest rates increase borrowing costs and can make it harder to raise capital, potentially impacting ALDX's R&D and operational runway.

Regulatory Environment / Drug Approval Landscape: For a biotech like ALDX, especially after receiving a Complete Response Letter (CRL) for its lead dry eye drug reproxalap, the overall regulatory climate and the FDA's scrutiny on drug efficacy are critical. A stringent regulatory environment can delay or deny approvals, impacting revenue prospects. [cite: 25 (from previous output)]

Market Risk Appetite for Speculative Assets: Global market conditions, including geopolitical tensions (Middle East Conflict), can increase overall market volatility and reduce investor appetite for higher-risk, growth-oriented biotechnology stocks. This affects ALDX's stock price and ability to attract investment, especially given its current developmental stage and recent setbacks.